National Health (Listed drugs on F1 or F2) Amendment Determination 2016 (No. 12) (PB 112 of 2016) (Cth)

PB 112 of 2016

National Health (Listed drugs on F1 or F2) Amendment Determination 2016 (No. 12)

National Health Act 1953

I, DIANNA PROSSER, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Aged Care, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated    21  December 2016

DIANNA PROSSER

Assistant Secretary (Acting)

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2016 (No. 12).

(2)   This Determination may also be cited as PB 112 of 2016.

1. Commencement

This Determination commences on 1 January 2017.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Glycine with carbohydrate

Omit

Glycomacropeptide and essential amino acids

[2]     Schedule 1, after item dealing with Goserelin

Insert

Grazoprevir with elbasvir

[3]     Schedule 1, after item dealing with Melphalan

Insert

Mepolizumab

[4]     Schedule 1, after item dealing with Milk powder-lactose free formula

Omit

Milk powder-lactose modified

[5]     Schedule 1, after item dealing with Rilpivirine

Insert

Riociguat